• Zealand Pharma launched the registrational Phase 3 ZUPREME program for once-weekly petrelintide in chronic weight management.
• Results have not been presented; the program is intended to generate evidence for future regulatory filings and marketing applications.
• Phase 3a comprises three placebo-controlled trials across obesity or overweight populations, including type 2 diabetes or established cardiovascular disease.
• Enrollment is expected to total about 7,000 participants, positioning petrelintide for a potential large-scale commercial opportunity.
• The decision follows earlier Phase 2 data indicating meaningful weight loss with tolerability broadly comparable to placebo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zealand Pharma A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609221100PRIMZONEFULLFEED1001274046) on September 22, 2026, and is solely responsible for the information contained therein.